Key Takeaway: Xeris Biopharma Holdings, Inc. has announced significant updates to its Board of Directors. CEO John Shannon will take on the role of Chair of the Board, while Marla Persky transitions to Lead Independent Director. Additionally, Nerissa Kreher, M.D. has been appointed to the board, effective July 1, 2026.
Price reaction · baseline $7.74 (2026-06-29 close) · hit pre-market · 2 other XERS headline(s) in the window, move may be shared
Appointment of experienced professionals to the board.
CEO John Shannon's new role enhances governance.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+113%
120-day peak, hindsight
Typical move
9.8%
average across 3 past catalysts
Lead asset
Glucagon
Phase 3 · Diabetes Mellitus, Type 1
Full Press Release Details
Chief Executive Officer John Shannon named Chair of the Board Marla Persky to transition to Lead Independent Director of the Board Board appoints Nerissa Kreher, M.D., effective July 1, 2026 CHICAGO --(BUSINESS WIRE)--Jun. 30, 2026-- Xeris Biopharma Holdings, Inc.
Frequently Asked Questions
Who is the new Chair of the Board at Xeris?
CEO John Shannon has been named Chair of the Board.
What is Marla Persky's new role?
Marla Persky will transition to Lead Independent Director.
When will Nerissa Kreher join the board?
Nerissa Kreher, M.D. will join the board effective July 1, 2026.